HEMISPHERx Starts Ph II With Ampligen

20 January 1997

- HEMISPHERx has begun a Phase II trial with Ampligen (poly I: polyC12U) in untreated HIV patients with CD4 levels over 400 cells/mm3. Previous studies have shown that HIV patients with CD4 levels greater than 300 cells/mm3 and treated with Ampligen, were less likely to develop AIDS compared to placebo. Ampligen is also in Phase II trials for the treatment of chronic fatigue syndrome, and has proved active in hepatitis B and renal cell carcinoma.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight